About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker ABBV · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 23, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761262 ↗
Letter or label ↗
Oct 23, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Efficacy
BLA761105 ↗
Letter or label ↗
Oct 14, 2026CANASA
MESALAMINE
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA021252 ↗
Sep 29, 2026Natrelle Silicone-Filled Breast Implants and Natrelle INSPI…
Prosthesis, breast, noninflatable, internal, silicone gel-f…
ABBV
Allergan
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P020056 ↗
Sep 25, 2026JUVMO
TAVAPADON
ABBV
Abbvie
New drug (NDA)
Type 1 - New Molecular Entity
NDA220415 ↗
Sep 11, 2026KYBELLA
DEOXYCHOLIC ACID
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA206333 ↗
Letter or label ↗
Sep 11, 2026KYBELLA
DEOXYCHOLIC ACID
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA206333 ↗
Letter or label ↗
Aug 11, 2026Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skin…
Implant, dermal, for aesthetic use
ABBV
Allergan
Device approval (PMA), supplement
Normal 180 Day Track
P110033 ↗
Aug 11, 2026Ultra, Ultra XC, Ultra Plus XC
Implant, dermal, for aesthetic use
ABBV
Allergan
Device approval (PMA), supplement
Normal 180 Day Track
P050047 ↗
Jul 23, 2026NORVIR
RITONAVIR
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA209512 ↗
Jul 23, 2026NORVIR
RITONAVIR
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA022417 ↗
Jul 23, 2026KALETRA
LOPINAVIR; RITONAVIR
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA021906 ↗
Jul 23, 2026KALETRA
LOPINAVIR; RITONAVIR
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA021251 ↗
Jun 30, 2026RINVOQ
UPADACITINIB
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA218347 ↗
Jun 30, 2026RINVOQ
UPADACITINIB
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA211675 ↗
Jun 26, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761262 ↗
Jun 26, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Efficacy
BLA761105 ↗
Jun 12, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761262 ↗
Jun 12, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Efficacy
BLA761105 ↗
Jun 11, 2026SKINVIVE by JUVEDERM®
Implant, dermal, for aesthetic use
ABBV
Allergan
Device approval (PMA), supplement
Panel Track
P110033 ↗
May 27, 2026DECNUPAZ
PIVEKIMAB SUNIRINE-PVZY
ABBV
Abbvie Inc
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761460 ↗
May 21, 2026LINZESS
LINACLOTIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA202811 ↗
May 20, 2026VENCLEXTA
VENETOCLAX
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA208573 ↗
May 6, 2026LUPRON
LEUPROLIDE ACETATE
ABBV
Abbvie Endocrine Inc
New drug (NDA), supplement
Labeling
NDA019010 ↗
Mar 31, 2026DEPAKOTE ER
DIVALPROEX SODIUM
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA021168 ↗
Letter or label ↗
Mar 31, 2026DEPAKOTE SPRINKLES
DIVALPROEX SODIUM
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA019680 ↗
Letter or label ↗
Mar 31, 2026DEPAKOTE
DIVALPROEX SODIUM
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA018723 ↗
Letter or label ↗
Mar 19, 2026VYALEV
FOSCARBIDOPA; FOSLEVODOPA
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA216962 ↗
Mar 19, 2026DUOPA
CARBIDOPA; LEVODOPA
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA203952 ↗
Mar 18, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761262 ↗
Mar 18, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761105 ↗
Mar 17, 2026COMBIGAN
BRIMONIDINE TARTRATE; TIMOLOL MALEATE
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA021398 ↗
Mar 11, 2026OZURDEX
DEXAMETHASONE
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA022315 ↗
Mar 6, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA761262 ↗
Mar 6, 2026SKYRIZI
RISANKIZUMAB-RZAA
ABBV
Abbvie Inc
Biologic (BLA), supplement
Efficacy
BLA761105 ↗
Feb 19, 2026VENCLEXTA
VENETOCLAX
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA208573 ↗
Jan 16, 2026Natrelle 133S Tissue ExpandersABBV
AbbVie
Device clearance (510(k))
Special
K254126 ↗
Dec 23, 2025HUMIRA
ADALIMUMAB
ABBV
Abbvie Inc
Biologic (BLA), supplement
Labeling
BLA125057 ↗
Dec 18, 2025VRAYLAR
CARIPRAZINE HYDROCHLORIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA204370 ↗
Dec 18, 2025VRAYLAR
CARIPRAZINE HYDROCHLORIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA204370 ↗
Dec 18, 2025VRAYLAR
CARIPRAZINE HYDROCHLORIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA204370 ↗
Dec 18, 2025VRAYLAR
CARIPRAZINE HYDROCHLORIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA204370 ↗
Dec 17, 2025ORIAHNN
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX S…
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA213388 ↗
Dec 17, 2025ORILISSA
ELAGOLIX SODIUM
ABBV
Abbvie
New drug (NDA), supplement
Labeling
NDA210450 ↗
Nov 25, 2025PRED MILD
PREDNISOLONE ACETATE
ABBV
Abbvie
New drug (NDA), supplement
Manufacturing (CMC)
NDA017100 ↗
Nov 14, 2025LUPRON DEPOT-PED
LEUPROLIDE ACETATE
ABBV
Abbvie Endocrine Inc
New drug (NDA), supplement
Labeling
NDA020263 ↗
Nov 4, 2025LINZESS
LINACLOTIDE
ABBV
Abbvie
New drug (NDA), supplement
Efficacy
NDA202811 ↗
Oct 21, 2025IMBRUVICA
IBRUTINIB
ABBV
Pharmacyclics LLC
New drug (NDA), supplement
Labeling
NDA217003 ↗
Oct 21, 2025IMBRUVICA
IBRUTINIB
ABBV
Pharmacyclics LLC
New drug (NDA), supplement
Labeling
NDA210563 ↗
Oct 21, 2025IMBRUVICA
IBRUTINIB
ABBV
Pharmacyclics LLC
New drug (NDA), supplement
Labeling
NDA205552 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:06 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates